机构:[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA
第一作者机构:[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.[2]Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA
通讯作者:
通讯机构:[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.[2]Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA
推荐引用方式(GB/T 7714):
Jianzhong Ai,Jia Li,Qin Su,et al.rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.[J].Gene therapy.2021,doi:10.1038/s41434-021-00275-5.
APA:
Jianzhong Ai,Jia Li,Qin Su,Hong Ma,Ran He...&Guangping Gao.(2021).rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression..Gene therapy,,
MLA:
Jianzhong Ai,et al."rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.".Gene therapy .(2021)